John Inzerillo, MD
Hematology & Oncology · Washington, NCNPI 1164404422
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,693 of the $5,065 with a category attached, or 72.9%. It is spread thinly across 40 manufacturers, the largest accounting for just 18.7%. Reporting peaked in 2019 at $1,865 and has fallen 83.3% since, to $311 in 2025.
Across 212 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$946
- E.r. Squibb & Sons, L.L.C.$542
- Dendreon Pharmaceuticals LLC$354
- Genentech USA, Inc.$337
- Novartis$316
- Seagen Inc.$273
- plus $2K from 34 others
Across 14 payments — averaging $7522.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Fujirebio Diagnostics, Incorporated$65K
- Pfizer$29K
- Jazz Pharmaceuticals Inc.$11K
What the payments were for
- Consulting fees$93018%
- Food & beverage$3,69373%
- Education$4419%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $946 |
| E.r. Squibb & Sons, L.L.C. | 25 | $542 |
| Dendreon Pharmaceuticals LLC | 17 | $354 |
| Genentech USA, Inc. | 11 | $337 |
| Novartis | 17 | $316 |
| Seagen Inc. | 10 | $273 |
| Pfizer | 13 | $267 |
| Johnson & Johnson | 14 | $263 |
| AstraZeneca(2 entities) | 12 | $217 |
| Merck | 11 | $187 |
| Lilly USA, LLC | 6 | $126 |
| Amgen | 8 | $124 |
| Sanofi | 6 | $100 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $98 |
| Gilead(2 entities) | 5 | $89 |
| Bristol Myers Squibb | 4 | $84 |
| Eisai Inc. | 5 | $78 |
| EMD Serono, Inc. | 5 | $69 |
| Bayer | 4 | $55 |
| Boehringer Ingelheim | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Puma Biotechnology, Inc. | 3 | $44 |
| Tempus AI, Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Incyte Corporation | 2 | $37 |
| Tesaro, Inc. | 2 | $33 |
| Myovant Sciences Inc. | 1 | $24 |
| Clovis Oncology, Inc. | 2 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Exelixis Inc. | 2 | $22 |
| AbbVie | 1 | $18 |
| Verastem, Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $14 |
| Beigene USA, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,065 in reported general payments places this provider in the 65th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 93 | $1,563,137 |
| XtandiEnzalutamide | 52 | $616,819 |
| TasignaNilotinib Hcl | 37 | $556,327 |
| Lenalidomide | 29 | $361,670 |
| PomalystPomalidomide | 18 | $341,810 |
| ImbruvicaIbrutinib | 34 | $340,693 |
| SprycelDasatinib | 13 | $184,720 |
| LynparzaOlaparib | 11 | $174,013 |
| VenclextaVenetoclax | 17 | $162,271 |
| RubracaRucaparib Camsylate | 11 | $144,027 |
| Abiraterone Acetate | 65 | $140,217 |
| EliquisApixaban | 42 | $33,099 |
| XareltoRivaroxaban | 28 | $21,035 |
| MyrbetriqMirabegron | 21 | $6,053 |
| OxycontinOxycodone Hcl | 11 | $5,575 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $84 | $1,563,13793 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $946 | $622,87273 claims |
| NovartisTasigna | $316 | $556,32737 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $542 | $526,53031 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $98 | $340,69334 claims |
| AstraZenecaLynparza | $217 | $174,01311 claims |
| AbbVieVenclexta | $18 | $162,27117 claims |
| Clovis Oncology, Inc.Rubraca | $24 | $144,02711 claims |
| PfizerEliquis | $267 | $33,09942 claims |
| Johnson & JohnsonXarelto | $263 | $21,03528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Washington
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.